AIMS/HYPOTHESIS: Type 2 diabetes is an established risk factor for cardiovascular disease (CVD). This increased risk may be due in part to the increased levels of inflammatory factors associated with diabetes. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a risk marker for CVD and has pro-inflammatory effects in atherosclerotic plaques. We therefore sought to determine whether Lp-PLA(2) levels partially explain the greater prevalence of subclinical CVD and greater incidence of CVD outcomes associated with type 2 diabetes in the Cardiovascular Health Study. METHODS: We conducted a cross-sectional and prospective study of 4,062 men and women without previous CVD from the Cardiovascular Health Study (1989 to 2007). Lp-PLA(2) mass and activity were measured in baseline plasma. Subclinical disease was determined at baseline and incident CVD was ascertained annually. We used logistic regression for cross-sectional analyses and Cox proportional hazards models for incident analyses. RESULTS: At baseline, Lp-PLA(2) mass did not differ significantly by type 2 diabetes status; however, Lp-PLA(2) activity was significantly higher among type 2 diabetic individuals. Baseline subclinical disease was significantly associated with baseline diabetes and this association was similar in models unadjusted or adjusted for Lp-PLA(2) (OR 1.68 [95% CI 1.31-2.15] vs OR 1.67 [95% CI 1.30-2.13]). Baseline type 2 diabetes was also significantly associated with incident CVD events, including fatal CHD, fatal myocardial infarction (MI) and non-fatal MI in multivariable analyses. There were no differences in these estimates after further adjustment for Lp-PLA(2) activity. CONCLUSIONS/ INTERPRETATION: In this older cohort, differences in Lp-PLA(2) activity did not explain any of the excess risk for subclinical disease or CVD outcomes related to diabetes.
AIMS/HYPOTHESIS: Type 2 diabetes is an established risk factor for cardiovascular disease (CVD). This increased risk may be due in part to the increased levels of inflammatory factors associated with diabetes. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a risk marker for CVD and has pro-inflammatory effects in atherosclerotic plaques. We therefore sought to determine whether Lp-PLA(2) levels partially explain the greater prevalence of subclinical CVD and greater incidence of CVD outcomes associated with type 2 diabetes in the Cardiovascular Health Study. METHODS: We conducted a cross-sectional and prospective study of 4,062 men and women without previous CVD from the Cardiovascular Health Study (1989 to 2007). Lp-PLA(2) mass and activity were measured in baseline plasma. Subclinical disease was determined at baseline and incident CVD was ascertained annually. We used logistic regression for cross-sectional analyses and Cox proportional hazards models for incident analyses. RESULTS: At baseline, Lp-PLA(2) mass did not differ significantly by type 2 diabetes status; however, Lp-PLA(2) activity was significantly higher among type 2 diabetic individuals. Baseline subclinical disease was significantly associated with baseline diabetes and this association was similar in models unadjusted or adjusted for Lp-PLA(2) (OR 1.68 [95% CI 1.31-2.15] vs OR 1.67 [95% CI 1.30-2.13]). Baseline type 2 diabetes was also significantly associated with incident CVD events, including fatal CHD, fatal myocardial infarction (MI) and non-fatal MI in multivariable analyses. There were no differences in these estimates after further adjustment for Lp-PLA(2) activity. CONCLUSIONS/ INTERPRETATION: In this older cohort, differences in Lp-PLA(2) activity did not explain any of the excess risk for subclinical disease or CVD outcomes related to diabetes.
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: L H Kuller; P Velentgas; J Barzilay; N J Beauchamp; D H O'Leary; P J Savage Journal: Arterioscler Thromb Vasc Biol Date: 2000-03 Impact factor: 8.311
Authors: J I Barzilay; C F Spiekerman; L H Kuller; G L Burke; V Bittner; J S Gottdiener; F L Brancati; T J Orchard; D H O'Leary; P J Savage Journal: Diabetes Care Date: 2001-07 Impact factor: 19.112
Authors: Hok-Hay S Oei; Irene M van der Meer; Albert Hofman; Peter J Koudstaal; Theo Stijnen; Monique M B Breteler; Jacqueline C M Witteman Journal: Circulation Date: 2005-02-08 Impact factor: 29.690
Authors: L H Kuller; L Shemanski; B M Psaty; N O Borhani; J Gardin; M N Haan; D H O'Leary; P J Savage; G S Tell; R Tracy Journal: Circulation Date: 1995-08-15 Impact factor: 29.690
Authors: Nancy Swords Jenny; Cam Solomon; Mary Cushman; Russell P Tracy; Jeanenne J Nelson; Bruce M Psaty; Curt D Furberg Journal: Atherosclerosis Date: 2009-09-20 Impact factor: 5.162
Authors: T L Nelson; M L Biggs; J R Kizer; M Cushman; J E Hokanson; C D Furberg; K J Mukamal Journal: J Clin Endocrinol Metab Date: 2012-03-07 Impact factor: 5.958
Authors: Julia Seyfarth; Thomas Reinehr; Annika Hoyer; Christina Reinauer; Christina Bächle; Beate Karges; Ertan Mayatepek; Michael Roden; Sabine E Hofer; Susanna Wiegand; Joachim Woelfle; Wieland Kiess; Joachim Rosenbauer; Reinhard W Holl; Thomas Meissner Journal: J Inherit Metab Dis Date: 2017-10-13 Impact factor: 4.982
Authors: Laura Jackisch; Warunee Kumsaiyai; Jonathan D Moore; Nasser Al-Daghri; Ioannis Kyrou; Thomas M Barber; Harpal Randeva; Sudhesh Kumar; Gyanendra Tripathi; Philip G McTernan Journal: Diabetologia Date: 2018-02-09 Impact factor: 10.122
Authors: Jorge R Kizer; Jason G Umans; Jianhui Zhu; Richard B Devereux; Robert L Wolfert; Elisa T Lee; Barbara V Howard Journal: Diabetes Care Date: 2012-02-14 Impact factor: 19.112
Authors: Jose Luis Sánchez-Quesada; Irene Vinagre; Elena De Juan-Franco; Juan Sánchez-Hernández; Rosa Bonet-Marques; Francisco Blanco-Vaca; Jordi Ordóñez-Llanos; Antonio Pérez Journal: Cardiovasc Diabetol Date: 2013-08-05 Impact factor: 9.951